NVAX Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of 18.06%. Novavax, Inc.'s return on equity of -- beat Merck & Co., Inc.'s return on equity of 39.63%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 48.15%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that Novavax, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Novavax, Inc. is more attractive than Merck & Co., Inc..

Novavax, Inc. has a beta of 2.583, which suggesting that the stock is 158.251% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Novavax, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Novavax, Inc.'s net income of -$202.4M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Novavax, Inc.'s price-to-earnings ratio is 4.92x while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.38x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of -19.69%. Novavax, Inc.'s return on equity of -- beat Moderna, Inc.'s return on equity of -30.18%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 48.15%. On the other hand Moderna, Inc. has an analysts' consensus of $39.00 which suggests that it could fall by -7.65%. Given that Novavax, Inc. has higher upside potential than Moderna, Inc., analysts believe Novavax, Inc. is more attractive than Moderna, Inc..

Novavax, Inc. has a beta of 2.583, which suggesting that the stock is 158.251% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Novavax, Inc.'s net income of -$202.4M is lower than Moderna, Inc.'s net income of -$200M. Notably, Novavax, Inc.'s price-to-earnings ratio is 4.92x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.38x versus 7.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of -9.34%. Novavax, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 48.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 3.8%. Given that Novavax, Inc. has higher upside potential than Pfizer Inc., analysts believe Novavax, Inc. is more attractive than Pfizer Inc..

Novavax, Inc. has a beta of 2.583, which suggesting that the stock is 158.251% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.24% to investors and pays a quarterly dividend of $0.43 per share. Novavax, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Novavax, Inc.'s net income of -$202.4M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Novavax, Inc.'s price-to-earnings ratio is 4.92x while Pfizer Inc.'s PE ratio is 20.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.38x versus 2.51x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of -316.61%. Novavax, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 48.15%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1898.55%. Given that Plus Therapeutics, Inc. has higher upside potential than Novavax, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Novavax, Inc..

Novavax, Inc. has a beta of 2.583, which suggesting that the stock is 158.251% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Novavax, Inc.'s net income of -$202.4M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Novavax, Inc.'s price-to-earnings ratio is 4.92x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.38x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.